RUBIN PAUL D 4

What Happened
Paul D. Rubin, Chief Medical Officer of BioAge Labs, was granted a derivative award for 110,000 shares on 2026-02-17. The grant is reported at $0.00 per share (no cash paid or proceeds) and is recorded as an "A" (award/grant) transaction rather than an open-market purchase or sale. This is a compensation award and not an immediate sale.

Key Details

• Transaction date: 2026-02-17; filing date: 2026-02-19 (filed timely).
• Amount: 110,000 derivative shares reported at $0.00 per share (total reported value $0).
• Shares owned after transaction: not specified in the filing.
• Transaction code: A (award/grant); reported as a derivative acquisition.
• Footnote: Award vests 1/48th per month (monthly tranches), with the first tranche vested on Feb 1, 2026, subject to Rubin’s continued service on each vesting date.

Context
This was a standard equity compensation award to an executive, not an open-market buy or sale. Derivative awards like this typically vest over time to align incentives; they do not necessarily indicate immediate bullish or bearish trading by the insider. No cashless exercise, tax-withholding, or sale was reported in this filing.